Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
Stopped The reason for the end of recruitment is that the recruitment target could not be achieved despite all efforts and the G-BA (financing party) does not consider a continuation of the AlloRelapseMM study to be expedient.
Conditions
Interventions
- DRUG: Allogeneic Stem Cells
- DRUG: carfilzomib/lenalidomide/dexamethasone (KRD)
- DRUG: elotuzumab/lenalidomide/dexamethasone (ERD)
- DRUG: daratumumab/bortezomib/dexamethasone (DVD)
- DRUG: daratumumab/lenalidomide/dexamethasone (DRD)
- DRUG: ixazomib/lenalidomide/dexamethasone (IRD)
- DRUG: pomalidomide/bortezomib/dexamethasone (PVD)
- DRUG: carfilzomib/daratumumab/dexamethasone (KDD)
- DRUG: Autologous Stem Cells
- DRUG: daratumumab/pomalidomide/dexamethasone (DPD)
- DRUG: isatuximab/carfilzomib/dexamethasone (Isa-KD)
- DRUG: selinexor/bortezomib/dexamethasone (SVD)
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
- [object Object]
- [object Object]